2811103525 6979422768 Λεβήνου 74, Ηράκλειο gorgoraptisp@gmail.com


 

Benign Prostatic Hyperplasia


 

What is the prostate and what role does it play?

The prostate gland is a small, chestnut-shaped organ with a normal size of about 20cc that lies below the bladder and surrounds the beginning of the urethra. Its role is the production of the prostatic fluid, which contains valuable components for the nutrition and liquefaction of the sperm, thus participating in the reproductive process.

What is Benign Prostatic Hyperplasia?

Benign prostatic hyperplasia (BPH) is the progressive increase in the size of the gland observed after the age of 40. The increase in the size of the prostate, and specifically its transition zone that compresses the wall of the urethra circularly, but also the bladder upwards, causes disturbances in urination called lower urinary tract symptoms (LUTS). It is an extremely common condition, since 4 out of 10 men show symptoms as early as their 5th decade of life.

 

 

     
     
 

What is it due to?

It is attributed to a disturbance in the balance of androgens, estrogens, growth factors and neurotransmitters in the prostate cell. It has a familial effect since it occurs more often in men with first-degree relatives who have the condition. In fact, the existence of a gene responsible for the disease has been suggested mainly in patients with a large prostate size who undergo surgical treatment before the age of 60. It is more often observed in men who are obese, lead a sedentary life, suffer from metabolic syndrome and have erectile problems. Men with hypogonadism, i.e. a lack of testosterone, will rarely develop the disease, which suggests the strong relationship of the condition to androgens. It also appears that the condition is less common in herbivores due to the antiandrogenic effect of phytoestrogens.

 

What does it have to do with prostate cancer?

It is worth emphasizing that BPH is not related to prostate cancer and its presence does not predispose to its development. After all, the two diseases develop in a different part of the organ and with different mechanisms. However, the diseases can coexist, which is why a test is always done to rule out prostate cancer. In benign prostatic hyperplasia, we often see increased PSA, the specific prostate antigen that is produced by prostate cells normally but is also used as a cancer marker. We evaluate the PSA in relation to the size of the prostate, the speed of its increase over time and the PSA ratio which will give us information about the possibility of malignancy. Of course, when there are indications, the patient will need to undergo a prostate biopsy to rule out possible malignancy.

What are the symptoms of CKD?

The symptoms of CKD, i.e. symptoms from the lower urinary system, are divided into those related to the storage of urine in the bladder (storage symptoms) and those related to the expulsion of urine from the bladder (urination symptoms)

Storage symptoms are:
•        Frequency, when small amounts cause the regular need to urinate.
•        Nocturia, when we wake up at night to urinate.
•        Urgency, when we cannot postpone urination.
•        Urge incontinence, when we do not have time to go to the toilet and have a loss of urine

Urinary symptoms are:
•        Decreased urine flow, when the radius of urine decreases.
•        Difficulty starting to urinate.
•        Intermittent urination.
•        Loss of drops of urine after the end of urination.
•        Feeling of incomplete emptying, i.e. the feeling that the bladder has not emptied completely.
•        Complete inability to urinate, the so-called urinary retention.

 

The only solution, then, to this extremely unpleasant experience is immediate catheter placement, since the pain of the obstruction is unbearable.
Other symptoms are pain in the bladder mainly during urination, especially in cases of urinary infection, as well as hematuria, usually in cases of lithiasis of the bladder.

The symptoms of prostatic hyperplasia strongly afflict men because:
•        Their daily professional and social activity is limited, since frequent visits to the toilet interrupt them.
•        Their sleep is disturbed, and thus they feel a permanent fatigue.
•        Many times, they do not have time to go to the toilet and lose urine resulting in soiling their pants (incontinence).
•        Erectile dysfunction also occurs.
These experiences may be accompanied by feelings of shame, decreased self-confidence, and depressive symptoms.

 

How can the disease progress?

In fact, the prostate grows, but the bladder suffers, since its responsibility is both the storage of urine and its elimination, i.e. urination. So, to be able to overcome the prostate barrier, the bladder muscle is overfed, to exert more pressure on the urine, so that it overcomes the blockage.
In general, we talk about medium glands when they are over 40 grams and large ones over 80 grams. Of course, this is not absolute, since the effect on urination is also determined by its composition. Thus, a small gland of 30 grams can even cause urinary retention, whereas a prostate even over 100 grams can cause mild or moderate symptoms. Also, the presence of a medial lobe projecting into the bladder is usually a significant problem since it further obstructs the flow of urine.
The hypertrophy of the bladder cannot, however, continue indefinitely. Due to the chronically increased pressures, the bladder gradually loses its elasticity and thus from a certain point a quantity of urine remains after urination, the so-called residual urine. A residual urine of more than 100ml is considered pathological, since it shows that the bladder is not contracting sufficiently. Also, stagnant urine can become infected, resulting in UTIs. The existence of residual urine is also a predisposing factor for the formation of stones in the bladder. Gallstones can cause pain and often hematuria.
Slowly, the remnant increases and the thickness of the cyst wall decreases and passively the cyst stretches. Thus, the residual can reach 2 to 3 liters. In such neglected conditions, the urine produced in the kidneys cannot go down into the bladder, the kidney calyxes stretch and lose their shape – that is, the so-called hydronephrosis occurs. If the obstruction persists and a catheter is not immediately placed, the parenchyma of the kidney is destroyed, and the patient develops renal failure.

 

Diagnosis of the condition

  Diagnosis will begin with taking a medical history. The type of discomfort, how severe it is, the time of its appearance and its frequency are key elements that will be asked by your doctor. For a better picture of the problem, your doctor will ask you to fill in a special questionnaire (International Prostate Symptom Questionnaire-IPSS). This is followed by the clinical examination which includes the digital examination of the prostate. It is a basic examination, since it gives the first information on the size of the gland, its constitution and possible suspicion of hardness in the constitution of the prostate, a point suspected of coexisting malignancy.
The basic examination is the measurement of urine flow, i.e. uroflow. The patient urinates inside a special machine that measures the flow, the amount of urine excreted and the time of urination. Usually the test is completed with an ultrasound of the kidneys, ureters, bladder and prostate as well as with an assessment of the residual urine, i.e. the amount of urine that remains in the bladder after urination.
During the first visit, the doctor may ask you for a general and urine culture, as well as some blood tests, such as urea and creatinine, to check kidney function. You will also usually be asked to have a prostate specific antigen (PSA) test.
In some cases, an endoscopic examination, cystoscopy, is performed, where, with a special flexible tool with a small camera on the end, we observe the urethra, prostate and bladder with direct vision.
Finally, in special cases, an additional imaging test is used, the CT scan of the upper and lower abdomen, as well as the urodynamic test, a special test that studies the function of the bladder and urethra. The purpose of all examinations is for the doctor to distinguish the effects of the condition, so that he can determine the correct therapeutic strategy in collaboration with the patient.

Treatment of prostatic hyperplasia

Today, there are many treatment options, capable of solving every man's problem. Your urologist will recommend the most suitable ones for you and help you decide which one to follow. The decision is always made on an individual basis based on the man's history, test findings and wishes.

-Active monitoring.
This is recommended for patients with mild symptoms, which do not have significant effects on their daily life. This treatment option includes changes in the patient's lifestyle, dietary changes, fluid control and restriction before going to bed at night, urinating before going to bed, avoiding coffee and alcohol that have a diuretic and irritating effect, treating constipation, controlling medicines that the patient uses for other conditions and possibly worsen the symptoms. A large proportion of men on active surveillance will not need additional treatment for 5 years.



Medication

Recommended for men with moderate or severe symptoms. Traditionally there are two major classes of drugs, α-blockers and 5α-reductase inhibitors. Additionally and depending on the symptoms, we also use antimuscarinic drugs, phosphodiesterase inhibitors, phytotherapy as well as combination treatments.
We usually start treatment with an α-blocker. There are several formulations in this class with similar efficacy and a similar side effect profile. The ones mainly available in Greece are alfuzosin, tamsulosin and silodosin. These drugs interfere with the dynamic element of the obstruction, causing a breakdown of the smooth muscle fibers of the prostate and the bladder neck without affecting the size of the prostate. They are safe drugs and will provide symptom improvement in two-thirds of our patients. These drugs can cause mild hypotension and for this reason we usually advise taking them at night before going to bed. Another possible side effect is the reduction or elimination of sperm, without affecting the hardness of the erection or the orgasm. This is due to a quantity of sperm returning to the bladder due to a breakdown of the internal sphincter. This is called retrograde ejaculation and is restored after stopping the drug.
The second class of drugs are the 5α reductase inhibitors (finasteride and dutasteride). They are drugs that reduce the size of the prostate by about 25-30% within a period of 6 months. We usually recommend them to men with larger prostates over 50 grams with moderate or severe symptoms. 5α-reductase inhibitors are the only drugs that reduce the likelihood of urinary retention, need for future surgery, and progression of benign hyperplasia. However, like all drugs, they can have side effects and the main one that can be observed in 20% of men is the reduction of sexual desire.
In men with moderate or severe symptoms and large prostates, a common contemporary option is combination therapy with an α-blocker and a 5α-reductase inhibitor. There is even a formulation available, i.e. in one capsule there are both components. The reception takes place in the evening. Combination therapy is a safe and effective option with an optimal result, but it can cumulatively accumulate the side effects of both drugs. The doctor will discuss all this with the man and the treatment decision will be made individually, depending on the wishes and expectations of the patient.
Anticholinergics alone or in combination with an α-blocker may be tried in men with predominant symptoms of overactive bladder, ie, urgency, frequency, nocturia, and urge incontinence. In these men, of course, the possibility of something else being hidden behind these symptoms, such as bladder cancer and lithiasis, must first be ruled out. Antimuscarinics act on the bladder causing damage to its wall. They are generally safe drugs and the most common side effects they may experience are constipation and dry mouth.
Phosphodiesterase inhibitors are excellent drugs for erectile dysfunction. In the last decade, large published studies have shown that in addition to improving erections, they can also improve symptoms from the lower urinary tract due to benign prostatic hyperplasia. Today, tadalafil is commercially available at a low dose of 5 mg for daily administration. It is a very good choice for men who have both symptoms of benign hyperplasia and erectile dysfunction. The problem in Greece is that it is not prescribed through the funds and the man pays the full cost of the medicine.
Phytotherapy is a common choice in men with benign hyperplasia that causes mild symptoms and is steadily gaining ground in the treatment of BPH. The problem is that there are no large randomized studies that give clear results. The exact mechanism of action of phytotherapy is not clear. In the laboratory they appear to have anti-inflammatory and anti-androgenic properties, but this has not been sufficiently confirmed in humans. In general, however, great care is needed with preparations sold over the internet. Always consult your doctor!
Whatever medication is chosen, it is extremely important to monitor the man over time with a specific monitoring program determined according to the therapeutic effect.

Surgical treatment

Surgical treatment is indicated when, despite medication, the patient's symptoms persist and significantly affect the quality of his life, or when we have complications related to the K.Y.P.
The absolute indications for surgical treatment of BPH are urinary retention, renal failure due to obstruction, recurrent hematuria due to BPH, cystitis, bladder diverticulum, and recurrent UTIs. Large and worsening residual urine may also be an indication for surgical intervention.
Today, the most frequent indication for surgical treatment is the relief of "annoying" lower urinary tract symptoms due to BPH that are resistant to drug therapy.

Classic (unipolar) Transurethral Resection of the Prostate (TUR-P, Transurethral Resection of the Prostate)
It is an endoscopic operation, in which the obstructing part of the prostate gland is removed through the urethra. With endoscopic techniques it is possible today to achieve the same surgical results as in the past with open surgical techniques, while at the same time operations through the urethra are less traumatic and with significantly lower rates of complications and side effects. After surgery, symptoms improve in 70–90% of patients. IPSS score decreases by approximately 85% and peak urine flow increases by 8–18ml/sec. The most common complication is retrograde ejaculation.

     
     
 

Open prostatectomy

Open prostatectomy is the oldest surgical technique for treating benign hyperplasia. The prostate adenoma is enucleated, either by transvesical access (Freyer) or through the anterior prostatic capsule (Millin). It is preferred in cases where the prostatic adenoma is particularly large (usually >100 gr) and is difficult to remove endoscopically. It is also performed in patients with large bladder stones or in patients with large bladder diverticulum.

 

 

 

 

The TURis method / Bipolar transurethral prostatectomy in saline and plasma sublimation

The introduction and use of bipolar technology is one of the most important developments in transurethral prostatectomy. The bipolar transurethral prostatectomy is essentially a technical modification of the conventional (classical) unipolar transurethral prostatectomy, where instead of using a conventional unipolar current, a bipolar electrode and current are used. The advantage of bipolar technology is that it allows tissue to be excised, using normal saline as an induction medium. This theoretically offers the possibility of handling larger glands and prolonging the operative time, without, however, worsening the perioperative safety of the patient. Bipolar devices differ in the mechanism by which the bipolar current is delivered to the tissue to achieve the desired effect.
Transurethral resection in normal saline and plasma sublimation (TURis) is a relatively new surgical method for the treatment of BPH. The technique got its name from the acronym (TransUrethal Resection in saline, TURis). This means transurethral resection in saline and introduces a radical innovation in the use of saline (sodium chloride) as a lavage solution.
It is an innovative and alternative method to the classic transurethral resection of the prostate, with which the tissues are removed with greater safety and with less bleeding, while the surgical time is significantly reduced.
During the removal of the prostate with plasma technology, the prostate is cut and removed in the form of small pieces with the help of an electric bracket that works with a bipolar current and the whole operation is carried out under a continuous flow of saline.
In contrast to plasma technology, conventional transurethral resection is performed using an electrical bracket with a unipolar current and in an environment of hypotonic water solution to ensure the conduction of the current, resulting in the more frequent occurrence of intraoperative and/or postoperative complications (TUR-syndrome).

 

 

     
     
 

In conclusion, the advantages of using bipolar versus conventional monopolar diathermy in transurethral prostatectomy are:

• use of normal saline as a flushing solution and therefore elimination of absorption syndrome (TUR-syndrome)
• possibility of extending the resection time in a large prostate gland
• reducing the degree of intraoperative and postoperative bleeding
• less tissue conduction trauma
• less thermal damage to the surrounding tissues
• reduction of electrical stimulation of the thyroid nerve
Benign Prostatic Hyperplasia is the most common benign urological condition in men after the age of 50 and can significantly affect men's quality of life and overall health. The options are careful monitoring, medication, and surgical treatment. The decision is always made in collaboration with the patient and after proper information from his urologist.